52 citations
,
January 2022 in “Current Research in Pharmacology and Drug Discovery” This review highlights ongoing efforts in drug repurposing and development of new therapeutics against COVID-19, emphasizing the promise of these strategies in addressing the challenges posed by SARS-CoV-2 mutations and post-infection complications.
1250 citations
,
August 2021 in “Scientific Reports” In this study, researchers estimated that 80% of patients infected with SARS-CoV-2 experienced at least one long-term symptom, with fatigue being the most common.
68 citations
,
May 2021 in “Endocrine” This review discusses the emerging "endocrine phenotype" of COVID-19, highlighting the implications for managing diabetes, obesity, vitamin D deficiency, and other endocrine conditions in affected patients.
9 citations
,
March 2021 in “Hormones” This review discusses how COVID-19 may affect gonadal function and potential gender differences, but reports no clinical results; it highlights possible mechanisms and new treatment approaches from recent literature.
737 citations
,
August 2020 in “Journal of Infection” This study found that most patients hospitalized for COVID-19 experienced persistent symptoms over 100 days post-admission, with no significant difference in symptoms between those treated in regular wards and intensive care units.
77 citations
,
July 2020 in “European Journal of Clinical Pharmacology” This review explores potential early-stage pharmacologic interventions for COVID-19 by targeting virus entry into host cells, identifying several existing drugs for further investigation, but reports no new clinical results.